HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ND 322

an SB-3CT prodrug; structure in first source

Also Known As:

ND-322; ND322 cpd

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bayles, Ian: 1 article (11/2016)
2.	Bedogni, Barbara: 1 article (11/2016)
3.	Chang, Mayland: 1 article (11/2016)
4.	Gao, Ming: 1 article (11/2016)
5.	Gooyit, Major: 1 article (11/2016)
6.	Ma, Jun: 1 article (11/2016)
7.	Marusak, Charles: 1 article (11/2016)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2016 - "The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination."
2.	Neoplasm Metastasis (Metastasis) 11/01/2016 - "These data support ND-322 as a novel effective inhibitor capable of counteracting both MT1-MMP and MMP2, two key proteases involved in melanoma growth and metastasis. "
3.	Melanoma (Melanoma, Malignant) 11/01/2016 - "ND-322 may therefore represent a new inhibitor in the repertoire of treatments against melanoma." 11/01/2016 - "Here we show that the novel small-molecule inhibitor ND-322 with high selectivity for MT1-MMP and MMP2, effectively inhibits MT1-MMP and MMP2 activity resulting in reduced in vitro melanoma cell growth, migration and invasion. " 11/01/2016 - "These data support ND-322 as a novel effective inhibitor capable of counteracting both MT1-MMP and MMP2, two key proteases involved in melanoma growth and metastasis. " 11/01/2016 - "The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination."

Related Drugs and Biologics

1.	Matrix Metalloproteinase 14 (MT1-MMP)
2.	Matrix Metalloproteinases (MMPs)
3.	Peptide Hydrolases (Proteases)
4.	ethylene sulfide (thiirane)